Related Experiment Video
Updated: May 23, 2025
06:07
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
5.6K
Prefectural Survey on Immune Checkpoint Inhibitor-Associated Myocarditis at the Start of the Basic Plan to Promote
Yuji Okura1, Satoru Miura2, Naohito Tanabe3
1Department of Onco-Cardiology, Niigata Cancer Center Hospital Niigata Japan.
Circulation Reports
|March 11, 2025
Summary
Cardiologists and oncologists report less experience with immune checkpoint inhibitor-associated myocarditis (ICIAM) than anthracycline-related cardiomyopathy (ARCM). Interdepartmental collaboration is needed to improve patient care for ICIAM.
Area of Science:
- Cardiology
- Oncology
- Public Health
Background:
- Japan's 2023 Basic Plan promotes integrated cancer and cardiovascular disease control programs.
- This study assesses collaboration between cardiologists and oncologists in Niigata Prefecture.
Purpose of the Study:
- To evaluate the extent of collaboration between cardiologists and oncologists regarding cancer therapies.
- To compare experiences and collaboration for immune checkpoint inhibitor-associated myocarditis (ICIAM) and anthracycline-related cardiomyopathy (ARCM).
Main Methods:
- Surveys distributed to cardiologists and oncologists in Niigata Prefecture.
- 124 cardiologists and 41 oncologists from 29 hospitals responded.
- Data collected on clinical experience with ICIAM and ARCM, and interdepartmental consultations.
Main Results:
- Experience with ICIAM was significantly lower (31.8% cardiologists, 24.4% oncologists) than with ARCM (80.0% cardiologists, 58.5% oncologists).
- Senior cardiologists reported less ICIAM experience than junior colleagues.
- 60% of hospitals providing immunotherapy reported no consultation for ICIAM, versus 20% for ARCM.
Conclusions:
- Cardiologists and oncologists have less experience and face greater collaboration challenges with ICIAM compared to ARCM.
- Enhanced collaboration between cardiology and oncology departments is crucial for managing ICIAM.
Related Concept Videos
01:27Tumor Immunotherapy
457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457
01:30Cancer Vaccines
321
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
321